Clinical Outcomes of CLL and MCL Patients Treated With Ibrutinib: An Observational Retrospective Medical Chart Review From India
Phase of Trial: Phase IV
Latest Information Update: 21 Jan 2020
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors Johnson & Johnson
- 25 Jul 2019 Status changed from recruiting to completed.
- 21 Jun 2019 Planned End Date changed from 30 May 2019 to 10 Jul 2019.
- 21 Jun 2019 Planned primary completion date changed from 30 May 2019 to 28 Jun 2019.